CTA highlights the best articles from the month of September 2018
- A Question to Sponsors – Have We Gone Too Far?
- Patient-Centric Clinical Trials │ How to Navigate the Clinical Trials Highway
- Industry Viewpoints: Executing the Most Time Efficient and Cost-effective Oncology Clinical Trials
- The Top 5: July 2018
- Immuno-Oncology and Combination Trials: New Aspirations, Old Frustrations
Patient Recruitment Strategies for Rare Diseases – Part II: Obtaining Access to a Limited Patient Pool
Ramani A. Aiyer, Principal, Shasta BioVentures, offers a primer on patient recruitment strategies for rare disease clinical trials
Patient-Centric Clinical Trials │ How to Navigate the Clinical Trials Highway
Robert Greene, Founder and President, HungerNdThirst Foundation and Professional Patient, explains why patients should have easier access to clinical trials
Announcing ‘Patient Centricity Week’ on Clinical Trials Arena
Throughout this week, CTA will spotlight the continual rise of patient centricity
Industry Viewpoints: Investigator-Initiated Studies – A Challenge for Supply with IMPs?
Peter Orosz, Head of Clinical Supply Chain Management & Oncology, Boehringer Ingelheim, addresses the challenges of investigator-initiated clinical trials
Expert Insights: What Does the Future Hold for US Biosimilars?
Fern Barkalow, PhD, Oncology and Hematology Director, GlobalData, explores the future of biosimilars in light of the FDA’s recent move to bolster development
Industry Viewpoints: Executing the Most Time Efficient and Cost-effective Oncology Clinical Trials
Hedy Dion, BERG Health, talks to CTA’s Elizabeth Williams about how to execute the most time efficient and cost effective oncology clinical trials
Immuno-Oncology and Combination Trials: New Aspirations, Old Frustrations
Ramani A. Aiyer, Shasta BioVentures, explores the immuno-oncology landscape, shining a spotlight on the promise immunotherapy holds for the future
Read our magazine
Global Defence Technology is the essential reading material for decision-makers in the defence industry, bringing you the latest news and analysis in an exciting, interactive format.